Leukomet-LX Tablet SR is a sustained-release formulation combining Ambroxol (75mg), Levocetirizine (5mg), and Montelukast (10mg), designed for the comprehensive management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency and easing expectoration. Levocetirizine, a potent second-generation antihistamine, selectively inhibits peripheral H1 receptors, effectively reducing symptoms of allergic rhinitis such as sneezing, nasal congestion, and rhinorrhea without causing significant sedation. Montelukast, a leukotriene receptor antagonist, prevents leukotriene-mediated bronchoconstriction, inflammation, and mucus production, contributing to improved asthma control and prevention of exercise-induced bronchospasm. The sustained-release mechanism ensures prolonged therapeutic levels, enhancing patient compliance by reducing dosing frequency. Leukomet-LX is indicated for patients requiring simultaneous management of mucus hypersecretion, allergic symptoms, and bronchoconstriction, commonly seen in chronic bronchitis, allergic rhinitis, and asthma. It should be used under medical supervision, with caution advised in patients with hepatic impairment or hypersensitivity to any component. Adverse effects may include headache, gastrointestinal disturbances, and mild sedation. This combination therapy offers a multi-targeted approach to respiratory symptom management, improving overall patient outcomes.